FDA places hold on Inovio's VGX-3100

The Food and Drug Administration placed a clinical hold on Inovio Pharmaceuticals Inc.'s (Nasdaq: INO) Phase III program for VGX-3100. The stock price tumbled $1.37 to close at $6.99.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.